BMJ Open
March 1, 2026
Christina Mcanulty, Philippe Lavoie, Samuel Cyr et al.
BACKGROUND: Alcohol use disorder and treatment-resistant depression (TRD) often co-occur, presenting a major clinical challenge with limited effective treatments. However, ketamine produces rapid antidepressant effects and has shown promise in reducing alcohol use, and acceptance and commitment therapy (ACT) can be effective for both substance use and mood disorders. This study explores the...
The Nursing clinics of North America
March 1, 2026
Amanda Canada
Posttraumatic Stress Disorder (PTSD) and Alcohol Use Disorder (AUD) often co-occur, worsening outcomes, relapse rates, and treatment response. Ketamine produces rapid and sustained PTSD symptom reduction and reduces AUD relapse. Prazosin effectively treats PTSD-related nightmares and may reduce alcohol consumption in individuals with heightened autonomic reactivity. The dual complementary...
Journal of Psychopharmacology
February 23, 2026
Tiphaine Raingeard, Thomas Soeiro, Caroline Victorri-Vigneau et al.
Background: While ketamine is widely used in anesthesia and pain management, its non-medical use is increasing worldwide. In France, surveillance data indicate a sharp rise in ketamine-related disorders, but comprehensive characterization of affected patients and associated complications remains limited. Aims: To examine trends on ketamine in France from 2019 to 2023, and describe severe...
Addiction
February 16, 2026
Cassie Bloy, Ananya Sarma, Bethan Marsh et al.
1 citation
People with alcohol use disorder experience alterations in consciousness from 0.8 mg/kg intravenous ketamine administration. Ketamine's effects appear to be broadly consistent across three repeated infusions. Ketamine-related reductions in alcohol consumption do not appear to be mediated by the acute psychoactive effects of ketamine.
Addiction Science & Clinical Practice
February 4, 2026
Maya Appley, Jessica R Gray, Dima Abdulrahim et al.
1 citation
Non-medical ketamine use is becoming increasingly common in the United States (US), but awareness remains limited among US healthcare providers. Here we present the case of a young woman who developed severe ketamine use disorder in the setting of an acute exacerbation of chronic post-traumatic stress disorder (PTSD). She also demonstrated symptoms concerning for two known complications of...
General Hospital Psychiatry
2026
Peter R. Chai, E Lee, M A Hasdianda et al.
Application of psychedelics including ketamine may be important adjuncts in the treatment of alcohol and opioid use disorders. Most patients with alcohol or opioid use disorder (AUD/OUD) may present to the emergency department (ED) seeking care both for substance use and associated complaints. Understanding safety and preliminary efficacy of ketamine and other psychedelics to improve the care...
Theoretical and Natural Science
December 24, 2025
Yiyin Hu
Ketamine is a traditional anesthetic, which has attracted much attention in recent years for its rapid antidepressant effect. It has performed particularly well in the treatment of patients with intractable depression, marking major breakthrough in the area of mental illness treatment. However, with further research, its potential neurotoxicity has gradually emerged, especially in the case of...
Current Pain and Headache Reports
December 15, 2025
Alan D. Kaye, Madison C Wolf, Sarah I Dufour et al.
2 citations
Chronic pain and opioid use disorder (OUD) are highly prevalent and frequently co-occurring conditions that pose complex treatment challenges. While opioids are effective for pain management, prolonged use significantly enhances risk of developing substance dependence. Conversely, addiction-focused therapies often fail to relieve persistent somatic pain. Ketamine, an N-methyl-D-aspartate (NMDA)...
Advanced Science
December 14, 2025
Yong Wang, Jiangang Xu, Xinyu Zhou et al.
5 citations
Esketamine and ketamine are perioperative analgesics and anesthetics that have been widely adopted in clinical practice in Europe and the United States. However, their application in China remains in the early stages of exploration and implementation. Esketamine and ketamine exert their effects through multiple receptors and pathways, but primarily act through non-competitive antagonism of the...
Frontiers in Pharmacology
November 19, 2025
Yan Du, Qing Ma, Xingcui Gao et al.
Introduction Metabolic and gut microbiota (GM) disturbance play a significant role in the complex pathogenesis of substance dependence. Although levo-tetrahydropalmatine (l-THP) demonstrates therapeutic potential in drug addiction, the underlying mechanism remains elusive. Methods The efficacy of l-THP was assessed using a conditioned place preference (CPP) paradigm. In this research, we...